Zloza Laboratory

 

Zloza Laboratory
 

     Research Overview

     Andrew Zloza, MD, PhD

     Current Lab Members

     Lab Alumni

Research Overview

Our laboratory focuses on understanding the interplay between infections, cancer, and the immune system. We have discovered that non-oncogenic infections (those that do not directly cause cancer) regulate tumor occurrence and growth (in both negative and positive ways). Therefore, we strive to understand the mechanism underlying these effects and to translate our findings toward patient therapies against cancer.

News and Events

OCTOBER 2016 

Our Cell Reports article “Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death” is now published.
Access the article here

SEPTEMBER 2016

Congrats to the Zloza Laboratory on the funding of their study “Autologous double-humanized mouse model for the study of Pembrolizumab” (MISP # 55542) by Merck Sharp & Dohme Corp. 
 

The Zloza Laboratory has been awarded research funding from Gateway For Cancer Research for their proposed collaborative work with the Kaufman Laboratory (Rutgers) on the study “Combination Oncolytic Virus and PD-1 Blockade for Melanoma Treatment” (PI: Kaufman, Co-I: Zloza)
 

Congrats to the Zloza Laboratory on the acceptance of their manuscript “Low dose interleukin-2 (IL-2) impairs host anti-tumor immunity and inhibits therapeutic responses” for publication in Cancer Immunology, Immunotherapy in collaboration with the Kaufman Laboratory at Rutgers Cancer Institute.

AUGUST 2016

Congrats to the Zloza Laboratory on the acceptance of their manuscript “Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death” for publication in Cell Reports

Toward this effort we utilize a double-humanized patient-derived xenograft model and novel biotechnologies that we have developed. These allow us to conduct in vivo studies of a patient’s anti-cancer immune response in the context of that patient’s intact tumor microenvironment, and to efficiently target our therapies to the tumor microenvironment. Our goals are to discover new cancer immunotherapies and to develop a unified theory of infection, cancer, and autoimmunity. 
 

Contact Us

We welcome inquiries about our research and new collaboration opportunities. Please contact us!
andrew.zloza@rutgers.edu   

TRAFFIC ALERT
effective 3/6/17

 

 


 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health